 |
|
Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data
Terry A. Jacobson, MD;
Godfrey G. Griffiths, BComm(Hons);
Cristina Varas, MD, MS;
Douglas Gause, DrPH;
Jennifer C. Y. Sung, PharmD;
Christie M. Ballantyne, MD
Arch Intern Med. 2000;160:1361-1369.
Background When the National Cholesterol Education Program Adult Treatment Panel II (ATP II) guidelines were published, National Health and Nutrition Examination Survey III data for 1988 to 1991 were used to estimate the number of Americans requiring lipid-lowering therapy based on ATP II cut points. However, the guidelines recommend using clinical judgment to determine whether to initiate drug therapy in individuals whose low-density lipoprotein cholesterol levels remain above treatment goals with diet therapy but below the initiation level for drug therapy.
Methods We analyzed updated (1988-1994) National Health and Nutrition Examination Survey III data, based on a sample of 6796 adults aged 20 years and older, to estimate the numbers of American adults with an elevated low-density lipoprotein cholesterol level and requiring drug therapy using cut points vs clinical judgment as specified in ATP II guidelines.
Results Assuming a 10% low-density lipoprotein cholesterol reduction with diet, an estimated 10.4 million American adults require drug therapy based on ATP II cut points. If we include individuals for whom the guidelines recommend clinical judgment, the estimate increases to 28.4 million. The largest increase occurs in individuals without known coronary heart disease but with 2 or more risk factors: from 5.5 to 17.5 million. These high-risk individuals have low-density lipoprotein cholesterol concentrations similar to those in patients with coronary heart disease.
Conclusions Since the ATP II guidelines were published, clinical judgment has been informed by abundant clinical trial evidence establishing the safety and benefit of lipid-lowering therapy. The large number of individuals at high risk for coronary heart disease emphasizes the need for cost-effective therapy to extend treatment to the greatest number of individuals who may benefit.
From the Department of Medicine, Emory University School of Medicine, Atlanta, Ga (Dr Jacobson); PPD Pharmaco Corporation, Morrisville, NC (Mr Griffiths); Novartis Global Epidemiology, Barcelona, Spain (Dr Varas); Novartis Health Care Management, East Hanover, NJ (Drs Gause and Sung); and Department of Medicine, Baylor College of Medicine, Houston, Tex (Dr Ballantyne). Mr Griffiths is an employee of PPD Pharmaco Corporation, Morrisville, NC, which received funding from Novartus Pharmaceuticals Corporation for performing data analysis of the third National Health and Nutrition Examination Survey data set.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Molecular Imaging of Inflammation in Atherosclerosis With Targeted Ultrasound Detection of Vascular Cell Adhesion Molecule-1
Kaufmann et al.
Circulation 2007;116:276-284.
ABSTRACT
| FULL TEXT
Coronary CT Angiography
Schoepf et al.
Radiology 2007;244:48-63.
ABSTRACT
| FULL TEXT
Arterial Ultrasonography and Tonometry as Adjuncts to Cardiovascular Risk Stratification
Kullo and Malik
J Am Coll Cardiol 2007;49:1413-1426.
ABSTRACT
| FULL TEXT
Implications of Cardiac Risk and Low-Density Lipoprotein Cholesterol Distributions in the United States for the Diagnosis and Treatment of Dyslipidemia: Data From National Health and Nutrition Examination Survey 1999 to 2002
Keevil et al.
Circulation 2007;115:1363-1370.
ABSTRACT
| FULL TEXT
Introduction: Pharmacotherapy for Dyslipidemia
Dumo
Journal of Pharmacy Practice 2006;19:61-62.
Managing Abnormal Blood Lipids: A Collaborative Approach
Fletcher et al.
Circulation 2005;112:3184-3209.
ABSTRACT
| FULL TEXT
The Break-Even Point: When Medical Advances Are Less Important Than Improving the Fidelity With Which They Are Delivered
Woolf and Johnson
Ann Fam Med 2005;3:545-552.
ABSTRACT
| FULL TEXT
C-reactive protein for the prediction of cardiovascular risk: Ready for prime-time?
Hackam and Shumak
CMAJ 2004;170:1563-1565.
FULL TEXT
Selecting Asymptomatic Patients for Coronary Computed Tomography or Electrocardiographic Exercise Testing
Greenland and Gaziano
NEJM 2003;349:465-473.
FULL TEXT
Task force #4--how do we select patients for atherosclerosis imaging?
Wilson et al.
J Am Coll Cardiol 2003;41:1898-1906.
FULL TEXT
The New National Cholesterol Education Program Guidelines: Clinical Challenges for More Widespread Therapy of Lipids to Treat and Prevent Coronary Heart Disease
Eidelman et al.
Arch Intern Med 2002;162:2033-2036.
FULL TEXT
A Randomized Trial of the Effect of Community Pharmacist Intervention on Cholesterol Risk Management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP)
Tsuyuki et al.
Arch Intern Med 2002;162:1149-1155.
ABSTRACT
| FULL TEXT
Improving Coronary Heart Disease Risk Assessment in Asymptomatic People: Role of Traditional Risk Factors and Noninvasive Cardiovascular Tests
Greenland et al.
Circulation 2001;104:1863-1867.
FULL TEXT
In-Hospital Initiation of Lipid-Lowering Therapy for Patients With Coronary Heart Disease : The Time Is Now
Fonarow and Ballantyne
Circulation 2001;103:2768-2770.
FULL TEXT
"The Lower the Better" in Hypercholesterolemia Therapy: A Reliable Clinical Guideline?
Jacobson
ANN INTERN MED 2000;133:549-554.
ABSTRACT
| FULL TEXT
|
